

## **Supplementary Materials file**

**Pharmacological inhibition of lysine-specific demethylase 1A reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice by a mechanism involving decreased oxidative stress and inflammation; evidence for potential implications in human atherosclerosis**

Simona-Adriana Manea<sup>1#</sup>, Mihaela-Loredana Vlad<sup>1#</sup>, Alexandra-Gela Lazar<sup>1</sup>, Horia Muresian<sup>2</sup>,  
Maya Simionescu<sup>1</sup>, Adrian Manea<sup>1\*</sup>

<sup>1</sup> Institute of Cellular Biology and Pathology “Nicolae Simionescu” of the Romanian Academy,  
Bucharest, Romania

<sup>2</sup> University Hospital Bucharest, Cardiovascular Surgery Department, Bucharest, Romania

#

**These authors contributed equally to this work**

\*

**Corresponding author:**

**Adrian Manea, Ph.D.**

**e-mail:** adrian.manea@icbp.ro


**Institute of Cellular Biology and Pathology “Nicolae Simionescu” of the Romanian Academy,  
8, B.P. Hasdeu Street, 050568, Bucharest, Romania**

<b>Parameter</b>	<b>Values (n = 25)</b>
Gender: Female (F)/Male (M) (N, %)	9/16 (36%/64%)
Age (years)	64.2 ± 8.3
Body-mass index (BMI) (kg/m <sup>2</sup> )	26.1 ± 3.6
Current smoker (N, %)	16 (64%)
Former smoker (N, %)	4 (16%)
Alcohol consumption (N, %)	1 (4%)
Diabetes (N, %)	8 (32%)
Hypertension (N, %)	21 (84%)
<b>Other cardiac diseases</b>	
Coronary artery disease (CAD) (N, %)	9 (36%)
Peripheral artery disease (PAD) (N, %)	8 (32%)
Glucose (mg/dl)	110.8 ± 33.6
TC (mg/dl)	175.1 ± 59.4
CHOL LDL (mg/dl)	116.8 ± 50.2
CHOL HDL (mg/dl)	43.5 ± 11.3
TG (mg/dl)	120 ± 46.2
<b>Medication</b>	
Aspirin (N, %)	23 (92 %)
Insulin (N, %)	1 (4%)
Metformin (N, %)	7 (28%)
Sulphonylurea (N, %)	2 (8 %)
Statin (N, %)	24 (96 %)


**Table S1.** Clinical characteristics of the patients. TC: total cholesterol; CHOL LDL: cholesterol low-density lipoprotein fraction; CHOL HDL: cholesterol high-density lipoprotein fraction; TG: triglycerides.

<b>Gene</b>	<b>GeneBank® Accession Number</b>	<b>Sequences of oligonucleotide primers</b>
<b>Mouse Nox1</b>	NM_172203.2	S: 5'-CATCCAGTCTCCAAACATGACA-3' A: 5'-GCTACAGTGGCAATCACTCCAG-3'
<b>Mouse Nox2</b>	FJ168469.1	S: 5'-ACTCCTGGGTAGCACTGG-3' A: 5'-GTTCCTGTCCAGTTGTCTTCG-3'
<b>Mouse Nox4</b>	AF276957.1	S: 5'-TGAACATACAGTGAAGATTCCCTGAAC-3' A: 5'-GACACCCGTAGACCAGGAA-3'
<b>Mouse p22phox</b>	NM_007806.3	S: 5'-TGGCCTGATTCTCATCACTGG-3' A: 5'-GGGACAACCTCACAGAAACTC-3'
<b>Mouse MCP-1</b>	NM_011333.3	S: 5'-ACTGAAGCCAGCTCTCTTCCTC-3' A: 5'-TTCCTCTGGGTAGCACAGAC-3'
<b>Mouse TNF<math>\alpha</math></b>	NM_013693.3	S: 5'-GGTGCCTATGTCTCAGCCTCT-3' A: 5'-CATGGCTGGCACCACTAGTT-3'
<b>Mouse NOS2</b>	NM_010927.4	S: 5'-CAGAGGACCCAGAGACAAAGC-3' A: 5'-TGCTGAAACATTCCCTGTGC-3'
<b>Mouse <math>\beta</math>-Actin</b>	NM_007393.5	S: 5'-CGTGAAAAGATGACCCAGATCA-3' A: 5'-TGGTACGACCAGAGGCATACAG-3'
<b>Human Nox1</b>	NM_013955	S: 5'-CACAAAGAAAAATCCTGGGTCAA-3' A: 5'-GACAGCAGATTGCGACACACA-3'
<b>Human Nox2</b>	KU178009.1	S: 5'-TCACTTCCTCCACCAAAACC-3' A: 5'-CACCTTCTGTTGAGATGCC-3'
<b>Human Nox4</b>	NM_016931	S: 5'-TGGCTGCCATCTGGTGAATG-3' A: 5'-CAGCAGCCCTCCTGAAACATGC-3'
<b>Human Nox5</b>	NM_024505	S: 5'-CAGGCACCCAGAAAAGAAAGCAT-3' A: 5'-ATGTTGTCTGGACACCTCGA-3'
<b>Human p22phox</b>	NM_000101.4	S: 5'-GTTTGTGTGCCTGCTGGAGT-3' A: 5'-TGGGCGGCTGCTTGATGGT-3'
<b>Human <math>\beta</math>-Actin</b>	NM_001101	S: 5'-CTGGCACCCAGCACAATG-3' A: 5'- GCCGATCCACACGGAGTACT-3'


**Table S2.** Sequences of sense (S) and antisense (A) oligonucleotide primers used in real-time PCR assays.




**Figure S1.** LSD1 blockade suppresses the up-regulation of (A) MCP-1, (B) TNF $\alpha$ , and (C) NOS2 transcript levels in the atherosclerotic aorta of ApoE-/- (HD) mice. n=3, \*P < 0.05, \*\*P < 0.01. P-values were taken in relation to vehicle-treated ApoE-/- (ND) condition. # P < 0.05, ## P < 0.01. P-values were taken in relation to vehicle-treated ApoE-/- (HD) condition.




**Figure S2.** (A, B) LSD1 mediates the up-regulation of MMP9, but not MMP2 protein levels in the atherosclerotic aorta of ApoE-/- mice. (C, D) Representative immunoblots depicting the changes in MMP2 and MMP9 protein expression levels function of experimental condition. n=3-6, \*P < 0.05, \*\*P < 0.01. P-values were taken in relation to vehicle-treated ApoE-/- (ND) condition. # P < 0.05. P-value was taken in relation to vehicle-treated ApoE-/- (HD) condition.



**Figure S3.** Elevated mRNA expression levels of (A) LSD1/KDM1A, (B) KDM2A, (C) KDM3A, (D) KDM4A, (E) KDM5A, and (F) KDM5B subtypes are associated with a pro-inflammatory macrophage phenotype in vitro. n=4, \*\*\* $P < 0.001$ . P-values were taken in relation to resting macrophage phenotype (M0-like Mac) condition.



**Figure S4.** GSK2879552-induced pharmacological inhibition of LSD1 function suppresses the up-regulation of (A) Nox1, (B) Nox2, (C) Nox4, and (D) p22phox mRNA levels in cultured pro-inflammatory macrophages (M1-like Mac). n=4, \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. P-values were taken in relation to untreated conditions.



**Figure S5.** LSD1 blockade reduces the up-regulation of (A) MCP-1 and (B) TNF $\alpha$  transcript levels in cultured pro-inflammatory macrophages (M1-like Mac). n=4, \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. P-values were taken in relation to untreated conditions.